1. Pink Sheet

Capricor Eyes RMAT Designation Based On Interim Phase II Data

 
• By Mandy Jackson

Capricor reported positive interim Phase I/II results for its cell therapy designed to treat cardiomyopathy in DMD patients and said it plans to seek regenerative medicine advanced technology, breakthrough or both designations from the US FDA.

microscope

Capricor Therapeutics Inc. is considering whether to seek the US FDA's Regenerative Medicine Advanced Technology (RMAT) designation, a breakthrough therapy designation or both for CAP-1002 (allogeneic cardiosphere-derived cells) in the treatment of Duchenne muscular dystrophy (DMD) based on positive interim results from the ongoing 12-month Phase I/II HOPE clinical trial.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies